Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the acceptance of data from its Phase 2 trial, RELIEF-PHN-1, for investigational drug LX9211 in treating postherpetic neuralgia (PHN) at the AAN Annual Meeting in Boston.
The trial results will be presented on April 24, 2023. Previous data from December 2022 indicated LX9211's potential as an effective non-opioid treatment for neuropathic pain, following positive results from another trial, RELIEF-DPN-1, demonstrating significant pain reduction.
LX9211 targets neuropathic pain via AAK1 inhibition and has Fast Track designation from the FDA for diabetic peripheral neuropathic pain. Overall, the company aims to develop innovative medicines to transform patient care.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. Key executives, including CEO Lonnel Coats, CFO Jeffrey L. Wade, and CMO Craig Granowitz, will engage in a moderated discussion on April 19th at 10:15 AM ET.
The event will be streamed live, and the recording will be accessible for two weeks post-event on the company’s website. Lexicon is focused on developing innovative medicines through its Genome5000™ program, which has identified over 100 protein targets for various diseases.
With a commitment to transforming lives, Lexicon has one marketed medicine and is actively developing candidates for conditions like heart failure and diabetes.